scholarly journals The role of antimicrobial drops Okomistin® in combined chronic blepharoconjunctivitis treatment

2015 ◽  
Vol 8 (4) ◽  
pp. 55-60 ◽  
Author(s):  
Igor Anatilevich Makarov
Keyword(s):  
Combined Therapy ◽  
Combined Treatment ◽  
Treatment Method ◽  
Meibomian Gland ◽  
Eye Drops ◽  
Prevention Measures ◽  
Artificial Tears ◽  
Eyelid Margin ◽  
Treatment And Prevention ◽  
Gland Function

Purpose. The evaluation of antimicrobial drops Okomistin® efficacy in combined treatment of chronic blepharoconjunctivitis. Material and methods. 80 patients (160 eyes) with chronic blepharoconjunctivitis were monitored. Demodex acne was found in eyelids of 72 eyes, the growth of saprophytic microflora in 28 cases. The complex of treatment and prevention measures consisted of daily compresses of Сalendula aqueous solution, instillations of Okomistin® eye drops, artificial tears. In the research group, the ultrasound eyelid margin micromassage was performed, and eyelid D’Arsonval therapy in demodex acne cases. Results. More rapid acute illness relief was observed in the eyes of patients in whom physiotherapy treatment was performed. Okomistin® instillations allow achieving sterile conjunctival culture in 3-5 days. Combined therapy helps to restore meibomian gland function, to achieve long-term disease remission. Conclusions. Combined use of the Okomistin®, physiotherapy, hygiene procedures, artificial tears is an effective and safe treatment method for chronic blepharoconjunctivitis combined treatment.

scholarly journals Effects of chalazion and its treatments on the meibomian glands: a nonrandomized, prospective observation clinical study

2020 ◽  
Author(s):  
Junping Li ◽  
Dongping Li ◽  
Na Zhou ◽  
Mengying Qi ◽  
Yanzhu Luo ◽  
...  
Keyword(s):  
Clinical Study ◽  
Conservative Treatment ◽  
Treatment Method ◽  
Meibomian Gland ◽  
Short Term ◽  
Acinar Structure ◽  
Significant Difference ◽  
Gland Function ◽  
Imagej Software ◽  
Slit Lamp Microscopy

Abstract Background To observe the effects of chalazion and its treatments on meibomian gland function and morphology in the chalazion area.Methods This nonrandomized, prospective observational clinical study included 58 patients (67 eyelids) who were cured of chalazion, including 23 patients (23 eyelids) treated with a conservative method and 35 patients (44 eyelids) treated with surgery. Infrared meibomian gland photography combined with image analysis by ImageJ software was used to measure the chalazion area proportion. Slit-lamp microscopy was employed to evaluate meibomian gland function, and a confocal microscope was used to observe meibomian gland acinar morphology before treatment and 1 month after complete chalazion resolution.Results At 1 month after chalazion resolution, the original chalazion area showed meibomian gland loss according to infrared meibomian gland photography in both groups. In patients who received conservative treatment, the meibomian gland function parameters before treatment were 0.74±0.75, 0.48±0.67, and 1.22±0.60, respectively. One month after chalazion resolution, the parameters were 0.35±0.49, 0.17±0.49, and 0.91±0.60, respectively; there was significant difference (P<0.05). The proportion of the chalazion area before treatment was 14.90 (11.03, 25.3), and the proportion of meibomian gland loss at 1 month after chalazion resolution was 14.64 (10.33, 25.77); there was no significant difference (P>0.05). In patients who underwent surgery, the meibomian gland function parameters before surgery were 0.93±0.87, 1.07±0.70, and 1.59±0.76, respectively, and at 1 month after chalazion resolution, they were 0.93±0.82, 0.95±0.75, and 1.52±0.70, respectively; there was no significant difference (P>0.05). The proportion of the chalazion area before surgery was 14.90 (12.04, 21.6), and the proportion of meibomian gland loss at 1 month after chalazion resolution was 14.84 (11.31, 21.81); there was no significant difference (P>0.05). The acinar structure could not be observed clearly in the meibomian gland loss area in most patients.Conclusions Chalazion causes meibomian gland loss, and the range of meibomian gland loss is not related to the treatment method but to the range of chalazion itself. A hot compress as part of conservative treatment can improve meibomian gland function at the site of chalazion in the short term.

scholarly journals Effects of chalazion and its treatments on the meibomian glands: a nonrandomized, prospective observation clinical study

2020 ◽  
Author(s):  
Junping Li ◽  
Dongping Li ◽  
Na Zhou ◽  
Mengying Qi ◽  
Yanzhu Luo ◽  
...  
Keyword(s):  
Clinical Study ◽  
Conservative Treatment ◽  
Treatment Method ◽  
Meibomian Gland ◽  
Short Term ◽  
Acinar Structure ◽  
Significant Difference ◽  
Gland Function ◽  
Imagej Software ◽  
Slit Lamp Microscopy

Abstract Background To observe the effects of chalazion and its treatments on meibomian gland function and morphology in the chalazion area. Methods This nonrandomized, prospective observational clinical study included 58 patients (67 eyelids) who were cured of chalazion, including 23 patients (23 eyelids) treated with a conservative method and 35 patients (44 eyelids) treated with surgery. Infrared meibomian gland photography combined with image analysis by ImageJ software was used to measure the chalazion area proportion. Slit-lamp microscopy was employed to evaluate meibomian gland function, and a confocal microscope was used to observe meibomian gland acinar morphology before treatment and 1 month after complete chalazion resolution. Results At 1 month after chalazion resolution, the original chalazion area showed meibomian gland loss according to infrared meibomian gland photography in both groups. In patients who received conservative treatment, the meibomian gland function parameters before treatment were 0.74±0.75, 0.48±0.67, and 1.22±0.60, respectively. One month after chalazion resolution, the parameters were 0.35±0.49, 0.17±0.49, and 0.91±0.60, respectively; there was significant difference (P<0.05). The proportion of the chalazion area before treatment was 14.90 (11.03, 25.3), and the proportion of meibomian gland loss at 1 month after chalazion resolution was 14.64 (10.33, 25.77); there was no significant difference (P>0.05). In patients who underwent surgery, the meibomian gland function parameters before surgery were 0.93±0.87, 1.07±0.70, and 1.59±0.76, respectively, and at 1 month after chalazion resolution, they were 0.93±0.82, 0.95±0.75, and 1.52±0.70, respectively; there was no significant difference (P>0.05). The proportion of the chalazion area before surgery was 14.90 (12.04, 21.6), and the proportion of meibomian gland loss at 1 month after chalazion resolution was 14.84 (11.31, 21.81); there was no significant difference (P>0.05). The acinar structure could not be observed clearly in the meibomian gland loss area in most patients. Conclusions Chalazion causes meibomian gland loss, and the range of meibomian gland loss is not related to the treatment method but to the range of chalazion itself. A hot compress as part of conservative treatment can improve meibomian gland function at the site of chalazion in the short term.

scholarly journals Effects of chalazion and its treatments on the meibomian glands: a nonrandomized, prospective observation clinical study

2020 ◽  
Author(s):  
Junping Li ◽  
Dongping Li ◽  
Na Zhou ◽  
Mengying Qi ◽  
Yanzhu Luo ◽  
...  
Keyword(s):  
Clinical Study ◽  
Conservative Treatment ◽  
Treatment Method ◽  
Meibomian Gland ◽  
Short Term ◽  
Acinar Structure ◽  
Significant Difference ◽  
Gland Function ◽  
Imagej Software ◽  
Slit Lamp Microscopy

Abstract Background To observe the effects of chalazion and its treatments on meibomian gland function and morphology in the chalazion area. Methods This nonrandomized, prospective observational clinical study included 58 patients (67 eyelids) who were cured of chalazion, including 23 patients (23 eyelids) treated with a conservative method and 35 patients (44 eyelids) treated with surgery. Infrared meibomian gland photography combined with image analysis by ImageJ software was used to measure the chalazion area proportion. Slit-lamp microscopy was employed to evaluate meibomian gland function, and a confocal microscope was used to observe meibomian gland acinar morphology before treatment and 1 month after complete chalazion resolution. Results At 1 month after chalazion resolution, the original chalazion area showed meibomian gland loss according to infrared meibomian gland photography in both groups. In patients who received conservative treatment, the meibomian gland function parameters before treatment were 0.74±0.75, 0.48±0.67, and 1.22±0.60, respectively. One month after chalazion resolution, the parameters were 0.35±0.49, 0.17±0.49, and 0.91±0.60, respectively; there was significant difference (P<0.05). The proportion of the chalazion area before treatment was 14.90 (11.03, 25.3), and the proportion of meibomian gland loss at 1 month after chalazion resolution was 14.64 (10.33, 25.77); there was no significant difference (P>0.05). In patients who underwent surgery, the meibomian gland function parameters before surgery were 0.93±0.87, 1.07±0.70, and 1.59±0.76, respectively, and at 1 month after chalazion resolution, they were 0.93±0.82, 0.95±0.75, and 1.52±0.70, respectively; there was no significant difference (P>0.05). The proportion of the chalazion area before surgery was 14.90 (12.04, 21.6), and the proportion of meibomian gland loss at 1 month after chalazion resolution was 14.84 (11.31, 21.81); there was no significant difference (P>0.05). The acinar structure could not be observed clearly in the meibomian gland loss area in most patients. Conclusions Chalazion causes meibomian gland loss, and the range of meibomian gland loss is not related to the treatment method but to the range of chalazion itself. A hot compress as part of conservative treatment can improve meibomian gland function at the site of chalazion in the short term.

scholarly journals Recent development in the artificial treatment for dry eye disease

2020 ◽  
Vol 11 (3) ◽  
pp. 2848-2857 ◽  
Author(s):  
Priyavarshini R ◽  
Amit B Patil
Keyword(s):  
Environmental Changes ◽  
Tear Film ◽  
Meibomian Gland ◽  
Eye Disease ◽  
Eye Drops ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Artificial Tears ◽  
Dry Eyes ◽  
The Common

Eyes are the most important organs of the human body. The important parts of the eyes are conjunctiva, cornea, Iris, pupil, retina, sclera. Eye is protected by eyelid from external environment. The common eye disease is kerato conjunctivitis sicca (KCS) i.e dry eyes syndrome. Tear is secreted by a lacrimal gland which lubricates the eye. The dry eyes disease syndrome commonly is caused because tears are not secreted properly by the tear duct or the tear film gets evaporated from the surface of the eye due to various factors or due to environmental changes. Dry eyes disease caused due to age, environmental factor like increase in air pollution, increase in temperature, humidity in the atmosphere, using contact lens, medication also causes dry eyes. This article reviews the causes, symptoms, and recent treatment system of dry eyes disease. Dry eyes can be treated by using medications like artificial tears, Carmellose artificial tears eye drops, Cyclosporine A, Difluprednate, Lacrisert nutritional supplements, omega-3 fatty acids, etc. The therapy like Meibomian gland expression, Intense pulsed light, Lipiflow, etc. the dry eyes disease not only affecting human eye but it also affects animals like dogs and cat.

scholarly journals Effects of chalazion and its treatments on the meibomian glands: a nonrandomized, prospective observation clinical study

2020 ◽  
Author(s):  
Junping Li ◽  
Dongping Li ◽  
Na Zhou ◽  
Mengying Qi ◽  
Yanzhu Luo ◽  
...  
Keyword(s):  
Clinical Study ◽  
Conservative Treatment ◽  
Treatment Method ◽  
Meibomian Gland ◽  
Short Term ◽  
Acinar Structure ◽  
Significant Difference ◽  
Gland Function ◽  
Imagej Software ◽  
Slit Lamp Microscopy

Abstract Background: To observe the effects of chalazion and its treatments on meibomian gland function and morphology in the chalazion area. Methods: This nonrandomized, prospective observational clinical study included 58 patients (67 eyelids) who were cured of chalazion, including 23 patients (23 eyelids) treated with a conservative method and 35 patients (44 eyelids) treated with surgery. Infrared meibomian gland photography combined with image analysis by ImageJ software was used to measure the chalazion area proportion. Slit-lamp microscopy was employed to evaluate meibomian gland function, and a confocal microscope was used to observe meibomian gland acinar morphology before treatment and 1 month after complete chalazion resolution. Results: At 1 month after chalazion resolution, the original chalazion area showed meibomian gland loss according to infrared meibomian gland photography in both groups. In patients who received conservative treatment, the meibomian gland function parameters before treatment were 0.74±0.75, 0.48±0.67, and 1.22±0.60, respectively. One month after chalazion resolution, the parameters were 0.35±0.49, 0.17±0.49, and 0.91±0.60, respectively; there was significant difference (P<0.05). The proportion of the chalazion area before treatment was 14.90 (11.03, 25.3), and the proportion of meibomian gland loss at 1 month after chalazion resolution was 14.64 (10.33, 25.77); there was no significant difference (P>0.05). In patients who underwent surgery, the meibomian gland function parameters before surgery were 0.93±0.87, 1.07±0.70, and 1.59±0.76, respectively, and at 1 month after chalazion resolution, they were 0.93±0.82, 0.95±0.75, and 1.52±0.70, respectively; there was no significant difference (P>0.05). The proportion of the chalazion area before surgery was 14.90 (12.04, 21.6), and the proportion of meibomian gland loss at 1 month after chalazion resolution was 14.84 (11.31, 21.81); there was no significant difference (P>0.05). The acinar structure could not be observed clearly in the meibomian gland loss area in most patients. Conclusions: Chalazion causes meibomian gland loss, and the range of meibomian gland loss is not related to the treatment method but to the range of chalazion itself. A hot compress as part of conservative treatment can improve meibomian gland function at the site of chalazion in the short term.

COMBINATION OF POTASSIUM PERCHLORATE AND PROPYLTHIOURACIL IN THE TREATMENT OF THYROTOXICOSIS

1968 ◽  
Vol 57 (4) ◽  
pp. 565-577 ◽  
Author(s):  
K. E. Røkke ◽  
J. H. Vogt
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Metabolic Rate ◽  
Total Cholesterol ◽  
Basal Metabolic Rate ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Control Measures ◽  
Potassium Perchlorate ◽  
Plasma Total Cholesterol

ABSTRACT A report is given on 95 thyrotoxic patients treated with a combination of 400 mg propylthiouracil and 400 mg of potassium perchlorate. Perchlorate was stopped when a marked remission of symptoms was obtained, on an average after less than 7 weeks. Euthyroidism was found on an average after 7.2 weeks. The basal metabolic rate, PBI, plasma total cholesterol and weight showed a fairly rapid normalization. Thirteen of the 95 patients were given radio-iodine therapy shortly before drug therapy was started. The remaining 82 cases were grouped together with the 23 cases previously reported. Of the total of 105 cases, 96 became euthyroid on combined therapy. For the frequency of side-effects, the thirteen cases mentioned above were included, giving a total of 118 cases. Eight cases showed an increase in goitre size and 15 cases had other side-effects, of which three were granulocytopenia due to propylthiouracil. The possibility of a higher frequency of mainly minor side-effects on combined therapy has to be balanced against the seemingly rapid and reliable therapeutic effect. Combined treatment, perhaps with even smaller doses than reported here, can be recommended in selected cases of thyrotoxicosis where a shortening of the thyrotoxic state seems of importance, or possibly where difficulties due to iodine exposure may be anticipated, provided adequate control measures are taken.

scholarly journals Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Helena de Castro e Gloria ◽  
Laura Jesuíno Nogueira ◽  
Patrícia Bencke Grudzinski ◽  
Paola Victória da Costa Ghignatti ◽  
Temenouga Nikolova Guecheva ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Dna Damage ◽  
Cancer Cells ◽  
Mismatch Repair ◽  
Cell Cycle Progression ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Human Colon ◽  
Human Colon Cancer

Abstract Background The advances in colorectal cancer (CRC) treatment include the identification of deficiencies in Mismatch Repair (MMR) pathway to predict the benefit of adjuvant 5-fluorouracil (5-FU) and oxaliplatin for stage II CRC and immunotherapy. Defective MMR contributes to chemoresistance in CRC. A growing body of evidence supports the role of Poly-(ADP-ribose) polymerase (PARP) inhibitors, such as Olaparib, in the treatment of different subsets of cancer beyond the tumors with homologous recombination deficiencies. In this work we evaluated the effect of Olaparib on 5-FU cytotoxicity in MMR-deficient and proficient CRC cells and the mechanisms involved. Methods Human colon cancer cell lines, proficient (HT29) and deficient (HCT116) in MMR, were treated with 5-FU and Olaparib. Cytotoxicity was assessed by MTT and clonogenic assays, apoptosis induction and cell cycle progression by flow cytometry, DNA damage by comet assay. Adhesion and transwell migration assays were also performed. Results Our results showed enhancement of the 5-FU citotoxicity by Olaparib in MMR-deficient HCT116 colon cancer cells. Moreover, the combined treatment with Olaparib and 5-FU induced G2/M arrest, apoptosis and polyploidy in these cells. In MMR proficient HT29 cells, the Olaparib alone reduced clonogenic survival, induced DNA damage accumulation and decreased the adhesion and migration capacities. Conclusion Our results suggest benefits of Olaparib inclusion in CRC treatment, as combination with 5-FU for MMR deficient CRC and as monotherapy for MMR proficient CRC. Thus, combined therapy with Olaparib could be a strategy to overcome 5-FU chemotherapeutic resistance in MMR-deficient CRC.

Combined Peritoneal Dialysis and Hemodialysis: Our Experience Compared to Others

2003 ◽  
Vol 23 (2) ◽  
pp. 157-161 ◽  
Author(s):  
Mamta Agarwal ◽  
Patricia Clinard ◽  
John M. Burkart
Keyword(s):  
Peritoneal Dialysis ◽  
Control Volume ◽  
Combined Therapy ◽  
Care Center ◽  
Combined Treatment ◽  
Tertiary Care ◽  
Clinical Reason ◽  
Combined Modality ◽  
Number Of Patients ◽  
Solute Clearance

Objective To determine the clinical experience of using combined-modality [simultaneous hemodialysis (HD) and peritoneal dialysis (PD)] treatment in patients with end-stage renal disease. Design We reviewed data on 4 patients from our center that were treated with “combined-mode therapy.” We then conducted a retrospective survey by sending questionnaires to nephrologists in the US and Canada by mail and by posting the survey on the Internet. Data queried included number of patients on combined modality, solute clearances, albumin levels pre and post combined therapy, reasons for using combined therapy, duration and success of combined therapy, and reimbursement issues. Setting and Participants Ours is a tertiary-care center. Patients that were not doing well on PD alone were put on combined modality of treatment between 1992 and 1998. Main Outcome Measures Clinical improvement in the indication for which the participant was started on combined modality. Results In response to the survey, data on 27 patients were collected. These data were combined with data on 4 patients from our unit that had previously been treated with combined HD and PD. Most patients were reported to have more than one clinical reason for changing from PD to combined therapy. The main clinical reason for offering combined treatments was inadequate solute clearance (34%), followed by ultrafiltration problems (16%) and neuropathy (11%). Mean duration of time followed on combined treatment was 8.5 ± 0.12 months. Most patients tolerated combined treatment well and were reported to show improvement in the clinical reasons for which they needed the combined modality. Dual access and reimbursement issues were not a problem. There was no single method used for calculating total (HD, PD, and residual renal) solute clearance. No universal total solute clearance goal was reported. Conclusion Hemodialysis and PD are not mutually exclusive. They can be used in combination to achieve targeted solute clearances, to improve certain clinical conditions, and to control volume and blood pressure in a subset of patients. Further evaluation is needed to better establish the long-term outcomes of using combined modality. Total solute clearance goals and methods for determining total solute clearance need to be standardized.

Losartan Improves Adipose Tissue-Derived Stem Cell Niche by Inhibiting Transforming Growth Factor-β and Fibrosis in Skeletal Muscle Injury

2012 ◽  
Vol 21 (11) ◽  
pp. 2407-2424 ◽  
Author(s):  
Jin-Kyu Park ◽  
Mi-Ran Ki ◽  
Eun-Mi Lee ◽  
Ah-Young Kim ◽  
Sang-Young You ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Adipose Tissue ◽  
Stem Cell ◽  
Muscle Injury ◽  
Transforming Growth Factor ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Type I ◽  
Skeletal Muscle Injury ◽  
Losartan Treatment

Recently, adipose tissue-derived stem cells (ASCs) were emerged as an alternative, abundant, and easily accessible source of stem cell therapy. Previous studies revealed losartan (an angiotensin II type I receptor blocker) treatment promoted the healing of skeletal muscle by attenuation of the TGF-β signaling pathway, which inhibits muscle differentiation. Therefore, we hypothesized that a combined therapy using ASCs and losartan might dramatically improve the muscle remodeling after muscle injury. To determine the combined effect of losartan with ASC transplantation, we created a muscle laceration mouse model. EGFP-labeled ASCs were locally transplanted to the injured gastrocnemius muscle after muscle laceration. The dramatic muscle regeneration and the remarkably inhibited muscular fibrosis were observed by combined treatment. Transplanted ASCs fused with the injured or differentiating myofibers. Myotube formation was also enhanced by ASC+ satellite coculture and losartan treatment. Thus, the present study indicated that ASC transplantation effect for skeletal muscle injury can be dramatically improved by losartan treatment inducing better niche.

The lipid layer of tears: dependent on meibomian gland function

2004 ◽  
Vol 78 (3) ◽  
pp. 361-365 ◽  
Author(s):  
James P. McCulley ◽  
Ward E. Shine
Keyword(s):  
Meibomian Gland ◽  
Lipid Layer ◽  
Gland Function
Sign in / Sign up

Export Citation Format

Share Document